HomeAI · summaries
Storia in 3 fonti
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Imfinzi combination snags FDA approval for high-risk non-muscle invasive bladder cancer
The FDA has approved an immunotherapy combination therapy for adult patients with Bacillus Calmette-Guérin-naive, high-risk non-muscle invasive bladder cancer.The combination of…
- ·
medpagetoday.com
FDA OKs Immunotherapy-BCG Combo for High-Risk Bladder Cancer
Combination significantly improved disease-free survival in phase III trial
- ·
morningstar.com
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk…
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer